Adding to the development, the brokerage firm Motilal Oswal has maintained its ‘Buy’ rating on Sun Pharma, setting a target price of Rs 1,970 per share, indicating an upside potential of 22% ...

maintaining a "Buy" rating. Leading brokerage firms have shared their latest investment insights on IndusInd Bank, Marico, and Sun Pharma, highlighting key developments that could impact their stock ...

Samuel S Chowdhury, chairman of Square Pharmaceuticals, yesterday expressed his willingness to purchase 15 lakh shares of the company, valued at over Tk 32 crore at the current market price.

Montreal-based Knight Therapeutics has galloped in with CAD $120 million ($84 million) to pick up Endo’s Paladin Pharma unit in a move that stands to significantly expand its Canadian business.

Sun Pharma (Sun) is acquiring US-based early-stage ... We upgrade our rating on the stock to BUY (earlier Hold) with a higher target price of INR 1,895, based on 31x FY27E EPS (32x on FY26E ...

Motilal Oswal Group entities—India Business Excellence Fund IV (via MO Alternate Investment Advisors) and Motilal Oswal Finvest—have acquired over 60% of Megafine Pharma for approximately ₹460 crore.

D. Boral Capital reiterated their buy rating on shares of UroGen Pharma (NASDAQ:URGN – Free Report) in a report issued on Monday morning,Benzinga reports. D. Boral Capital currently has a $25.00 ...

Knight Therapeutics Inc. GUD-T has signed a deal to buy the assets of Paladin Pharma Inc. as the Canadian drug company looks to build out its domestic business after a strategic push into South ...

Sun Pharma will buy outstanding shares of the Waltham, Massachusetts-based Checkpoint for $4.10 each upfront, exercising a non-transferable contingent value of up to $0.70 per share in cash based ...

Sun Pharma will acquire Checkpoint Therapeutics for $4.10 per share, with a potential additional $0.70 CVR. FDA-approved Unloxcyt (cosibelimab-ipdl) for metastatic or locally advanced cSCC in ...

On Sunday, India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) for an upfront ...

New Jersey's pharmaceutical industry supports 370,000 jobs and generates $130 billion a year, or 20% of the state's economy. It already faced pushback in recent years from Democrats such as former ...